Latest Shire Plc American Depositary Shares (SHPG)
Post# of 94
Posted On: 03/13/2014 1:54:10 PM
Latest Shire Plc American Depositary Shares (SHPG) Headlines
Regulatory Setback for Sucampo in the U.K. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 13 mins ago
Sucampo's type II variation of Amitiza refused approval for opioid- induced constipation (OIC) in the U.K.
Pipeline Update at BioLineRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:50PM CDT
BioLineRx announced the successful completion of the single administration, dose-escalation stage of the ongoing phase I/II study on BL-7010
Roche Collaborates with Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:05PM CDT
Roche's Ventana Medical Systems, Inc. has entered into a multi-year agreement with Bayer Pharma AG, thereby extending an existing collaboration between the two companies.
Can Alexion Pharmaceuticals Continue to Deliver?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Successful biotechs are generally expected to reinvest their profits into the development of broad pipelines, but Alexion is following a somewhat different path. While I do not mean to give short shrift to this company's pipeline development...
Zogenix (ZGNX) Jumps: Stock Moves 11.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:25AM CDT
Zogenix was a big mover last session, with shares rising nearly 12%.
What Falling Estimates & Price Mean for Tetraphase Pharmaceuticals (TTPH) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:15AM CDT
One such stock that you may want to consider dropping is Tetraphase Pharmaceuticals which witnessed negative earnings estimate revisions in current quarter and current year.
New Diagnostic Test From Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 10:30AM CDT
Roche recently announced that its new diagnostic test, Elecsys Syphilis immunoassay, is now available in the markets.
Additional Positive Data on Omeros Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 5:50PM CDT
Omeros announced additional positive results from its phase IIa study on OMS824, for the treatment of schizophrenic patients.
NewLink Genetics' Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 12:36PM CDT
Share prices of NewLink Genetics fell 16.2% after the committee recommended continuation of its phase III pancreatic cancer study (IMPRESS) of HyperAcute Pancreas.
Update on Endo's Product Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 11:00AM CDT
The approval of Aveed has boosted Endo's top line.
Biogen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 10:40AM CDT
Biogen upgraded to Zacks Rank #1 (Strong Buy)
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Alcobra Gains IND Clearance for MDX - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:40PM CST
Alcobra's IND application for Metadoxine Extended Release (MDX) has been cleared by the U.S. FDA recently.
Forest Labs/Adamas Seek FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:00PM CST
Forest Labs/Adamas files NDA for fixed-dose combination of Namenda ER/Aricept
Profit from Orphan Drugs: 3 Choices (Revised) - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 07, 1:33PM CST
The orphan drugs sector is projected to grow globally at a CAGR of 5.67% from 2013 to 2018.
Rigel (RIGL) Worth Watching: Stock Rises 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:46AM CST
Rigel was a big mover last session, as the company saw its shares rise over 10% on the day.
Shire (SHPG): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:48AM CST
Shire (SHPG) sees solid earnings estimate revisions,stands out in a strong industry, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
Stock Market Closes Mixed; Ambarella Tops Expectations
at Investor's Business Daily - Thu Mar 06, 4:00PM CST
Stocks closed mixed Thursday, and after the bell Ambarella (AMBA) topped profit expectations. Ambarella, a maker of video chips, reported a 27% jump in sales to $40 million for the January-ended quarter. Adjusted earnings of 26 cents a share were...
Encouraging Data from Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:35PM CST
Roche (RHHBY) recently announced new encouraging data from phase IIb studies, LUTE / VERSE on asthma candidate lebrikizumab.
Stock Market Closes Mixed; Medical Leaders Drop
at Investor's Business Daily - Thu Mar 06, 3:13PM CST
Stocks closed mixed Thursday as the medical sector, one of the market's bulwarks, came under some selling. The Dow Jones industrial average led with a 0.4% gain, while the S&P 500 added 0.2% and the Nasdaq fell 0.2%. Volume fell across the board,...
Regulatory Setback for Sucampo in the U.K. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 13 mins ago
Sucampo's type II variation of Amitiza refused approval for opioid- induced constipation (OIC) in the U.K.
Pipeline Update at BioLineRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:50PM CDT
BioLineRx announced the successful completion of the single administration, dose-escalation stage of the ongoing phase I/II study on BL-7010
Roche Collaborates with Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:05PM CDT
Roche's Ventana Medical Systems, Inc. has entered into a multi-year agreement with Bayer Pharma AG, thereby extending an existing collaboration between the two companies.
Can Alexion Pharmaceuticals Continue to Deliver?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Successful biotechs are generally expected to reinvest their profits into the development of broad pipelines, but Alexion is following a somewhat different path. While I do not mean to give short shrift to this company's pipeline development...
Zogenix (ZGNX) Jumps: Stock Moves 11.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:25AM CDT
Zogenix was a big mover last session, with shares rising nearly 12%.
What Falling Estimates & Price Mean for Tetraphase Pharmaceuticals (TTPH) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:15AM CDT
One such stock that you may want to consider dropping is Tetraphase Pharmaceuticals which witnessed negative earnings estimate revisions in current quarter and current year.
New Diagnostic Test From Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 10:30AM CDT
Roche recently announced that its new diagnostic test, Elecsys Syphilis immunoassay, is now available in the markets.
Additional Positive Data on Omeros Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 5:50PM CDT
Omeros announced additional positive results from its phase IIa study on OMS824, for the treatment of schizophrenic patients.
NewLink Genetics' Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 12:36PM CDT
Share prices of NewLink Genetics fell 16.2% after the committee recommended continuation of its phase III pancreatic cancer study (IMPRESS) of HyperAcute Pancreas.
Update on Endo's Product Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 11:00AM CDT
The approval of Aveed has boosted Endo's top line.
Biogen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 10:40AM CDT
Biogen upgraded to Zacks Rank #1 (Strong Buy)
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Alcobra Gains IND Clearance for MDX - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:40PM CST
Alcobra's IND application for Metadoxine Extended Release (MDX) has been cleared by the U.S. FDA recently.
Forest Labs/Adamas Seek FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:00PM CST
Forest Labs/Adamas files NDA for fixed-dose combination of Namenda ER/Aricept
Profit from Orphan Drugs: 3 Choices (Revised) - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 07, 1:33PM CST
The orphan drugs sector is projected to grow globally at a CAGR of 5.67% from 2013 to 2018.
Rigel (RIGL) Worth Watching: Stock Rises 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:46AM CST
Rigel was a big mover last session, as the company saw its shares rise over 10% on the day.
Shire (SHPG): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:48AM CST
Shire (SHPG) sees solid earnings estimate revisions,stands out in a strong industry, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
Stock Market Closes Mixed; Ambarella Tops Expectations
at Investor's Business Daily - Thu Mar 06, 4:00PM CST
Stocks closed mixed Thursday, and after the bell Ambarella (AMBA) topped profit expectations. Ambarella, a maker of video chips, reported a 27% jump in sales to $40 million for the January-ended quarter. Adjusted earnings of 26 cents a share were...
Encouraging Data from Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:35PM CST
Roche (RHHBY) recently announced new encouraging data from phase IIb studies, LUTE / VERSE on asthma candidate lebrikizumab.
Stock Market Closes Mixed; Medical Leaders Drop
at Investor's Business Daily - Thu Mar 06, 3:13PM CST
Stocks closed mixed Thursday as the medical sector, one of the market's bulwarks, came under some selling. The Dow Jones industrial average led with a 0.4% gain, while the S&P 500 added 0.2% and the Nasdaq fell 0.2%. Volume fell across the board,...
(0)
(0)